Drugs / pbi-shRNA™ EWS/FLI1 Type 1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02736565 | Oct 2016 → Aug 2019 | Ewing sarcoma | Gradalis, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pbi-shRNA EWS/FLI1 Type 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02736565 ↗ |
| Route | Intravenous | “Lipoplex is given intravenously as a single administration twice a week for 4 weeks for a total of 8 infusions per cycle followed by 2 weeks of rest.” NCT02736565 ↗ |